Market: NASD |
Currency: USD
Address: 12278 Scripps Summit Drive
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Show more
📈 Fate Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$4.17
-
Upside/Downside from Analyst Target:
285.80%
-
Broker Call:
7
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
10-25%
-
Net Income Growth Range (1Y):
0-10%
-
Revenue Growth Range (1Y):
<0%
-
Upcoming Earnings Date:
2025-11-12
-
EPS Estimate:
-0.28
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Fate Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2025-11-11 (estimated upcoming) | - |
| 2025-08-12 | -0.29 |
| 2025-05-13 | -0.32 |
| 2025-03-05 | -0.44 |
| 2024-11-12 | -0.4 |
| 2024-08-13 | -0.33 |
| 2024-05-09 | -0.47 |
| 2024-02-26 | -0.45 |
| 2023-11-08 | -0.46 |
| 2023-08-08 | -0.54 |
| 2023-05-03 | -0.19 |
| 2023-02-28 | -0.58 |
| 2022-11-03 | -0.86 |
| 2022-08-03 | -0.78 |
| 2022-05-04 | -0.68 |
| 2022-02-28 | -0.72 |
| 2021-11-04 | -0.45 |
| 2021-08-04 | -0.58 |
| 2021-05-05 | -0.44 |
| 2021-02-24 | -0.61 |
| 2020-11-05 | -0.68 |
| 2020-08-05 | -0.35 |
| 2020-05-11 | -0.44 |
| 2020-03-02 | -0.37 |
| 2019-11-05 | -0.4 |
📰 Related News & Research
No related articles found for "fate therapeutics".
